Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation of Safety and Efficacy of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Ages greater than or equal to18 years and less than or equal to 50 years~Normal renal function: creatinine less than 1.5 mg/dl~Normal liver function: total bilirubin less than 1.5mg/dl, ALT and AST levels must be below the laboratory's high normal value.~Normal blood count:~WBC 3000-10000/mm(3)~Granulocytes greater than 1500/mm(3)~Platelets greater than 150,000/mm(3), and~Hemoglobin (females greater than 11.1 g/dl, males greater than 12.7 g/dl)~Antecubital veins must be adequate for peripheral access for phlebotomy (subject must be eligible for normal blood donation)~Ability to comprehend the investigational nature of the study and provide informed consent~EXCLUSION CRITERIA: ANY OF THE FOLLOWING:~Active infection or history of recurrent infection, hepatitis B and C (HBsAg, Anti-HCV), HIV and/or HTLV-1~History of autoimmune disease such as rheumatoid arthritis, systemic lupus erythematous~History of cancer within the past 5 years excluding basal cell or squamous cell carcinoma of the skin~History of any hematologic disorders including thromboembolic disease~History of cardiac disease such as uncontrolled hypertension, peripheral vascular disease, myocardial infarction, cardiac arrhythmias or related symptoms such as tachycardia, chest pain, shortness of breath which have required medical intervention or treatment or a Framingham coronary disease risk prediction score of greater than 10% 10 year CHD risk~History of cerebrovascular disease, transient ischemic attack, or stroke~Pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): AMD3100 given as a single 240 g/kg dose followed 14-90 days later by a single 320 g/kg dose
- 2 (Type: EXPERIMENTAL): AMD3100 given as a single 320 g/kg dose followed 14-90 days later by a single 400 g/kg dose
- 3 (Type: EXPERIMENTAL): AMD3100 given as a single 400 g/kg dose followed 14-90 days later by a single 480 g/kg dose.
- 4 (Type: EXPERIMENTAL): randomized to either receive 240 g/kg first followed by 480 g/kg after a washout period or 480 g/kg first followed by 240 g/kg after a washout period.

Based on this trial design, predict the completion outcome and termination type (if applicable).